scholarly journals A CASE OF LAPAROSCOPIC SPLENECTOMY FOR LOCAL RECURRENCE OF GASTRIC GIST AFTER TREATMENT WITH IMATINIB MESYLATE

2007 ◽  
Vol 68 (9) ◽  
pp. 2229-2232 ◽  
Author(s):  
Keisuke KOEDA ◽  
Akira SASAKI ◽  
Hisataka FUJIWARA ◽  
Masanori TAKAHASHI ◽  
Takehiro CHIBA ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Imatinib Mesylate ◽  
Laparoscopic Splenectomy ◽  
Gastric Gist

scholarly journals A Case of Liver Metastasis from Gastric GIST Resected after Imatinib Mesylate Therapy

2020 ◽  
Vol 81 (9) ◽  
pp. 1780-1785
Author(s):  
Yosuke MORIMOTO ◽  
Koji FUJITA ◽  
Hiroyuki KIKUNAGA ◽  
Hiroshi MIURA ◽  
Syojiro MORINAGA ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Imatinib Mesylate ◽  
Gastric Gist

Imatinib mesylate therapy in advanced gastrointestinal stromal tumors—A Regional cancer centre experience

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 19505-19505
Author(s):  
K. M. Patel ◽  
P. M. Shah ◽  
S. N. Shukla ◽  
B. J. Parikh ◽  
A. S. Anand ◽  
...  
Keyword(s):  
Local Recurrence ◽  
Imatinib Mesylate ◽  
Metastatic Disease ◽  
Gastrointestinal Stromal Tumors ◽  
Locally Advanced ◽  
Progression Free Survival ◽  
Free Survival ◽  
Stromal Tumors ◽  
Post Surgery

19505 Background: The treatment of gastrointestinal stromal tumors has been revolutionised by the advent of Imatinib, a specific tyrosine kinase inhibitor. Post operative local and metastatic recurrences of this tumor have been effectively managed by Imatinib. Here we present our experience of Imatinib in recurrent locally advanced/metastatic gastrointestinal stromal tumors (GIST). Methods: From Nov 2001 to Sep 2005, 33 patients with metastatic and / or locally advanced inoperable CD-117 positive GIST were offered imatinib mesylate therapy at 400 mg/day p.o. A total of 21 patients were evaluable for tumor response. Follow up period ranged from 4 months to 38 months with median follow up period being 18 months. Median age is 58 yrs, M:F ratio is 6:4. ECOG performance status was 0–1 in 70% (23 patients) and 2 in 30% (10 patients). 70% patients had post surgery recurrence. 2 patients (6%) had received adjuvant chemotherapy prior to recurrence. 30% (10 patients) had local recurrence, 40% (13 patients) had metastatic disease while 30% (10 patients) had local recurrence as well as metastatic disease. Results: Response evaluation was done by RECIST criteria. 15% (5 patient) showed CR while PR rates were 30% (10 patients). The overall major response (CR+PR) was 45%. The overall progression free survival was as high as 80%. All the patients who had a progression free survival also had a significant improvement in quality of life. Conclusions: Imatinib mesylate therapy shows significant survival benefits in locally advanced inoperable/metatstatic gastrointestinal stromal tumors. It will be a very long time before PET scan for evaluation and follow up becomes feasible in developing country setting. No significant financial relationships to disclose.

scholarly journals Malignant stromal tumor of the stomach with giant cystic liver metastases prior to treatment with imatinib mesylate

2013 ◽  
Vol 70 (2) ◽  
pp. 225-228 ◽  
Author(s):  
Radoje Colovic ◽  
Marjan Micev ◽  
Slavko Matic ◽  
Natasa Colovic ◽  
Nikica Grubor ◽  
...  
Keyword(s):  
Liver Metastases ◽  
Imatinib Mesylate ◽  
Left Lobe ◽  
Uneventful Recovery ◽  
Gastrointestinal Neoplasms ◽  
Gastric Gist ◽  
Tissue Samples ◽  
Billroth Ii Gastrectomy ◽  
Cystic Liver ◽  
The Right

Introduction. Gastrointestinal stromal tumors (GISTs) are rare and account for 0.1%-3% of all gastrointestinal neoplasms. GISTs are most commonly located in the stomach (60%) and 20%-25% are malignant, with metastases involving the peritoneum or the liver. Cystic liver metastases are extremely rare. Only two previous cases of patients with cystic liver metastases, prior to treatment with imatinib mesylate, have been described so far. Case report. We reported a 52-year-old woman presented with a history of abdominal fullness and discomfort. Clinical examination revealed two palpable masses, first in the right upper abdomen and second left to the umbilicus. Examinations revealed 4 cystic metastases in the liver, 3 in the right lobe (including a huge one measuring 20.5 x 16 cm), and 1 in the left lobe, together with a primary tumor on the greater curvature of the stomach. Gastric tumor was removed with a Billroth II gastrectomy. Partial excision of the largest liver metastasis was performed for histopathology. Immunohistochemistry confirmed the diagnosis of a GIST in both tissue samples. After an uneventful recovery the patient was commenced on imatinib mesylate therapy. The patient remainsed symptom-free at 24 months follow-up. Conclusion. This was the third reported case of gastric GIST with giant cystic liver metastases present prior to treatment with imatinib mesylate. Although extremely rare, GISTs may present with cystic liver metastases prior to treatment with imatinib mesylate, and should be considered in the differential diagnoses of patients with liver cysts of uncertain aetiology.

scholarly journals A CASE OF LIVER METASTASIS OF GASTRIC GIST RESECTED AFTER ADMINISTRATION OF IMATINIB MESYLATE

2007 ◽  
Vol 68 (2) ◽  
pp. 415-419 ◽  
Author(s):  
Kazuhiro MIGITA ◽  
Akihiko WATANABE ◽  
Chihiro SAKAMOTO ◽  
Takao OHYAMA ◽  
Hirofumi ISHIKAWA ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Imatinib Mesylate ◽  
Gastric Gist

scholarly journals A Large Gastric GIST with Peritoneal Dissemination Who Underwent Surgery to Control Infection Due to Abscess Formation during Imatinib Mesylate Therapy

2017 ◽  
Vol 50 (5) ◽  
pp. 350-356
Author(s):  
Jongsung Pak ◽  
Kazuyoshi Yamamoto ◽  
Kazuhiro Nishikawa ◽  
Motohiro Hirao ◽  
Masakazu Miyake ◽  
...  
Keyword(s):  
Imatinib Mesylate ◽  
Peritoneal Dissemination ◽  
Abscess Formation ◽  
Gastric Gist ◽  
Control Infection

scholarly journals Gastrointestinalni tumor zeluca (GIST) kao uzrok masivnog krvarenja iz gornjih partija digestivnog trakta

2007 ◽  
Vol 54 (1) ◽  
pp. 169-171 ◽  
Author(s):  
V.R. Djukic ◽  
A.R. Karamarkovic ◽  
S. Mijatovic ◽  
M. Micev ◽  
V.M. Bumbasirevic ◽  
...  
Keyword(s):  
Tyrosine Kinase ◽  
Imatinib Mesylate ◽  
Kinase Inhibitor ◽  
Complete Response ◽  
Response To Treatment ◽  
Gastric Gist ◽  
Adjuvant Imatinib ◽  
Mesenchymal Tumors ◽  
Promising Treatment ◽  
Histopathology Examination

Gastrointestinal stromal tumors GIST are rare mesenchymal tumors of the gastrointestinal tract characterized by expression of a receptor that activates tyrosine kinase called C- kit. Since malignant GIST has an extremely poor prognosis even after surgical resection. The development of a tyrosine kinase inhibitor, STI571/imatinib mesylate/Gleevec, Glivec which inhibits the BCR-ABL, PDGF-R alpha, and C-Kit receptors, has changed the management of unrespectable malignant GIST and has improved the survival of patients with metastaic disease. We report a 32 year old male patient with subcardiale gastric GIST and massive gastrointestinale bleeding. The patient underwent total gastrectomy, D2 lymphadenestomy, distal pancreatectomy and splenectomy on 02.02. 2004. Histopathology examination of the primary tumor revealed a strong C-Kit expression and CD 34 +++, Ki67 20 and so called "Pure GIST" was approved Liver metastasis was detected on ultrasound and CT 12 months later and segmentectomy S7 was performed on 23.03.2005. Postoperative course was uneventful. HP examination - malignant 35 x 30 mm sarcoma like tumor of mesenchymal origin. The patient received adjuvant imatinib -mesylate Gleevec Novartis Pharma Basel 400 mg a day. The initial complete response to treatment continued to 24 months postoperatively Imatinib is a recent and very promising treatment extirpation remains the only curative treatment of malignant GIST as evidenced by our patient.

Sign in / Sign up

Export Citation Format

Share Document